A phase I study of SU006668 [SU6668] via twice daily oral administration under fed conditions in patients with advanced malignancies.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2011
At a glance
- Drugs Orantinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 01 Jan 2008 New trial record.